Adarx Pharmaceuticals Inc ADRX

$13.80 +0.57 (4.31%)

Valuation

Market cap
1,412,977,000
Revenue TTM
$3,449,000
Net income TTM
$-73,088,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-2,119.11%
Debt to equity
0.00

Trading

Volume
357,000
Avg volume
—
Day's range
$12.70 – $13.99
Shares out
106,801,000
Stochastic %K
21%
Beta
—
Analysts
Strong Buy
Price target
$35.00

Price

Company profile

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran...

Show more

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(877) 232-7974
Website
https://www.adarx.com
Address
5871 Oberlin Drive, Suite 200, San Diego, United States

Latest news

Stocktwits

topstockalerts Nov 10, 1:29 AM
After Hours Top Gainers PT2 $WFF $RUBI $SANM $GP $ADRX
0 replies
Baazigar123 Nov 6, 8:41 PM
$ADRX few more
0 replies
ChazzyTrades Oct 27, 4:50 PM
$ADRX 🚀🚀
0 replies
Benitocalixto Oct 17, 2:49 PM
$PRQR $WVE $ADRX Also some more tidbits on ADRX - they were launched in 2019 - 7 years ago. (mostly explains why new candidates for PRQR/LLY and WVE/GSK collaborations haven’t been disclosed.) The original private investors in ADRX were Lilly Asia Ventures, Orbimed, Bain and TCG among others. All of these private specialists bought into the ADRX IPO - except for LLY, very interesting. Abbie was the big pharma company that bought into this IPO. PRQR and WVE have been partnered for development with Lilly and GSK going on 4-5 years now. Will remind you that LLY has bought into all of PRQR’s capital raises since 2022. GSK has bought into WVE’s raises since 2022, including the deal last December at $19.00 per share - this valued WVE at $3.6B 10 months ago. Insane. I suspect ADRX and CTY IPOs have something to do with the destroyed valuations for early leaders in RNA editing.
0 replies
Benitocalixto Oct 17, 1:11 PM
$PRQR $WVE $ADRX $CTY.X It's been a busy 2 weeks for IPOs in the RNA space, despite the awful environment for small cap biotechs. ADRX and CTY had highly successful IPOs. These new players use mRNA silencing technology - ADRX uses hepatic delivery and CTY goes beyond hepatic ($ARWR ). $ADRX mkt cap $1.9B and $850M cash, $CTY.X mkt cap $1.1B and $300M cash. CTY is preclinical/Phase 1 while ADRX has it's lead program (HAE) entering Phase 3 with topline readout late 2027. How is it possible that these new players can command these valuations when compared to $WVE and $PRQR. There is extreme dislocation here that will be resolved one way or another..
1 replies
SmartMoneySetups Oct 8, 1:11 PM
$ADRX — Adarx Pharmaceuticals · SR One Capital bought 592,593 sh — $10.07M at ~$17.00 — on 9/28, on top of director Simeon George's ~$27.2M across three buys in six months. Specialist biotech fund + director conviction stacking. • Entry: $16.40–17.20 · Stop: $14.90 · T1: $19.50 · T2: $21.50 · 1–3 mo. Half size — clinical-stage binary risk.
0 replies
tfinnerty Oct 5, 1:02 PM
$ADRX
0 replies
topstockalerts Oct 1, 11:48 PM
ADARx Pharmaceuticals announced that underwriters fully exercised their option to purchase an additional 3,937,500 common shares at $17 per share, with the transaction closing October 1, 2026. The exercise brings total shares sold in the company’s IPO to 30.1875 million, generating approximately $513.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. Separately, AbbVie purchased 5,255,542 ADARx shares at $17 per share through a concurrent private placement. Including the IPO, ADARx raised approximately $602.5 million in total gross proceeds before fees and expenses. The additional capital significantly expands ADARx’s funding base as it advances its pharmaceutical development programs. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank served as lead book-running managers, with LifeSci Capital acting as an additional bookrunner. $ADRX $ABBV
0 replies